Bio-Techne Corp (NASDAQ:TECH – Get Free Report) shares were up 7% on Wednesday following a stronger than expected earnings report. The company traded as high as $69.92 and last traded at $69.16. Approximately 2,958,199 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 2,450,796 shares. The stock had previously closed at $64.63.
The biotechnology company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.03. The business had revenue of $295.88 million for the quarter, compared to analyst estimates of $290.20 million. Bio-Techne had a return on equity of 13.59% and a net margin of 6.41%.Bio-Techne’s revenue was down .4% compared to the same quarter last year. During the same period last year, the firm posted $0.42 earnings per share.
Trending Headlines about Bio-Techne
Here are the key news stories impacting Bio-Techne this week:
- Positive Sentiment: Q2 beat: TECH reported EPS of $0.46 vs. consensus $0.43 and revenue of $295.9M vs. $290.2M expected — the upside likely drove the rally as results topped estimates. Techne (TECH) Beats Q2 Earnings and Revenue Estimates
- Positive Sentiment: Margin expansion: operating margin improved ~244 basis points year-over-year, showing better cost control and profitability even with flat organic sales — a constructive signal for earnings quality. TECH Q2 Earnings & Revenues Beat Estimates, Operating Margin Up
- Positive Sentiment: End-market demand: management cited robust demand in key drug-development product lines, supporting near-term revenue resilience and product-level strength. Biotech firm Bio-Techne beats quarterly estimates on strength in key unit
- Positive Sentiment: Dividend: the Board declared a $0.08 quarterly dividend payable Feb. 27 (record Feb. 16), which supports income-oriented investor interest. Bio-Techne Declares Dividend
- Neutral Sentiment: Company release & calls: the formal Q2 press release and earnings-call transcript are available for details on segment performance and management commentary. Review the call for any guidance updates. Bio-Techne (TECH) Q2 2026 Earnings Call Transcript Bio-Techne Releases Second Quarter Fiscal 2026 Results
- Neutral Sentiment: Analyst / valuation pieces: recent articles evaluate TECH’s valuation (post-product launches) and whether the recent rebound is justified — useful for framing upside vs. valuation risk. A Look At Bio Techne (TECH) Valuation After Cultrex Synthetic Hydrogel Launch
- Negative Sentiment: Growth weakness: organic sales were flat and reported revenue was down ~0.4% year-over-year, underscoring that margin gains were driven more by efficiency than top-line growth — a potential concern for investors focused on growth trajectory. Bio-Techne Releases Second Quarter Fiscal 2026 Results
Analyst Ratings Changes
Get Our Latest Research Report on Bio-Techne
Institutional Investors Weigh In On Bio-Techne
Several institutional investors and hedge funds have recently made changes to their positions in TECH. Nicholas Company Inc. lifted its stake in shares of Bio-Techne by 6.5% in the fourth quarter. Nicholas Company Inc. now owns 390,794 shares of the biotechnology company’s stock worth $22,983,000 after acquiring an additional 23,785 shares during the period. Swiss Life Asset Management Ltd raised its holdings in Bio-Techne by 4.6% during the 4th quarter. Swiss Life Asset Management Ltd now owns 7,526 shares of the biotechnology company’s stock worth $443,000 after purchasing an additional 328 shares during the last quarter. Bryn Mawr Trust Advisors LLC bought a new position in Bio-Techne during the 4th quarter worth approximately $223,000. Ethic Inc. lifted its position in shares of Bio-Techne by 7.5% in the 4th quarter. Ethic Inc. now owns 5,259 shares of the biotechnology company’s stock worth $309,000 after purchasing an additional 367 shares during the period. Finally, Sequoia Financial Advisors LLC boosted its stake in shares of Bio-Techne by 2.8% in the 4th quarter. Sequoia Financial Advisors LLC now owns 11,405 shares of the biotechnology company’s stock valued at $671,000 after purchasing an additional 310 shares during the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.
Bio-Techne Stock Performance
The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.81 and a current ratio of 4.22. The stock’s 50 day moving average price is $63.15 and its 200 day moving average price is $59.14. The company has a market capitalization of $10.74 billion, a P/E ratio of 141.60, a price-to-earnings-growth ratio of 4.50 and a beta of 1.48.
About Bio-Techne
Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.
Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.
Further Reading
- Five stocks we like better than Bio-Techne
- Why This NYSE Biotech Matters in 2026
- Wall Street Turns Bullish on USAU as Gold Hits New Record!
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- What a Former CIA Agent Knows About the Coming Collapse
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
